AKRO Stock Overview Together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Akero Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Akero Therapeutics Historical stock prices Current Share Price US$54.08 52 Week High US$58.40 52 Week Low US$15.32 Beta -0.20 1 Month Change 94.39% 3 Month Change 67.27% 1 Year Change 159.88% 3 Year Change 203.82% 5 Year Change 107.28% Change since IPO 195.20%
Recent News & Updates Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $350 million. Jan 30
Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $350 million. Jan 29
President notifies of intention to sell stock Jan 28
Some Good MASH/NASH News From Akero Therapeutics Jan 28 Akero Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.
New major risk - Share price stability Jan 27 See more updates Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $350 million. Jan 30
Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $350 million. Jan 29
President notifies of intention to sell stock Jan 28
Some Good MASH/NASH News From Akero Therapeutics Jan 28 Akero Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.
New major risk - Share price stability Jan 27
Price target increased by 23% to US$56.82 Jan 27
Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 Synchrony Real-World Study Evaluating Efruxifermin (Efx) in Patients with Non-Invasively Diagnosed Mash or MASLD Jan 13
Co-Founder recently sold US$280k worth of stock Jan 07
Co-Founder notifies of intention to sell stock Jan 03
Akero Therapeutics: Where This Potential MASH Play Stands Currently Dec 31
President recently sold US$242k worth of stock Dec 15
President exercised options and sold US$275k worth of stock Dec 08
Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024 Nov 16
Akero Therapeutics, Inc. Provides Business Update Nov 08
Insider notifies of intention to sell stock Nov 04
Insider notifies of intention to sell stock Oct 17
Co-Founder notifies of intention to sell stock Oct 03
Akero Therapeutics: Good Candidate For The MASH Basket Sep 20
Insider notifies of intention to sell stock Sep 18
Insider notifies of intention to sell stock Aug 25
New major risk - Revenue and earnings growth Aug 12
Executive VP notifies of intention to sell stock Jul 18
Co-Founder notifies of intention to sell stock Jul 04
New major risk - Revenue and earnings growth Jun 09
Insufficient new directors May 01
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer Apr 30 Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc
Co-Founder notifies of intention to sell stock Apr 03
Akero Therapeutics' EFX Data Warrants Caution Apr 03
Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology Mar 08 Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million. Mar 07
President notifies of intention to sell stock Mar 06 Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million. Mar 06
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
Price target increased by 13% to US$48.38 Mar 04
Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program Mar 04
New major risk - Revenue and earnings growth Mar 01
New minor risk - Share price stability Feb 28
Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program Dec 18
President exercised options and sold US$368k worth of stock Dec 13
Co-Founder recently sold US$440k worth of stock Nov 24
Price target decreased by 29% to US$48.44 Oct 12
Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins Oct 11
New major risk - Share price stability Oct 11
Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH Oct 10
Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology Oct 05
President notifies of intention to sell stock Oct 04
Price target increased by 7.3% to US$67.75 Sep 13
Price target increased by 7.7% to US$64.75 Sep 05
Insider notifies of intention to sell stock Aug 31
Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023 Aug 29
President exercised options and sold US$920k worth of stock Aug 06
Co-Founder & Chief Scientific Officer notifies of intention to sell stock Jun 29 Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index
Co-Founder & Chief Scientific Officer recently sold US$2.1m worth of stock Jun 25
Co-Founder & Chief Scientific Officer notifies of intention to sell stock Jun 19
President exercised options and sold US$1.1m worth of stock Jun 10
Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study Jun 06
President exercised options and sold US$1.1m worth of stock May 06
President notifies of intention to sell stock Apr 06
President exercised options and sold US$1.2m worth of stock Mar 10
President exercised options and sold US$1.2m worth of stock Feb 07
Insider notifies of intention to sell stock Jan 20
Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy Jan 11
Co-Founder exercised options and sold US$544k worth of stock Dec 30
Price target increased to US$52.00 Dec 27
Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study Dec 22
President exercised options and sold US$455k worth of stock Dec 10
Independent Director recently sold US$1.1m worth of stock Dec 03
President exercised options and sold US$428k worth of stock Nov 04
Independent Director recently sold US$12m worth of stock Oct 29
Price target increased to US$48.33 Oct 07
Co-Founder & Chief Scientific Officer exercised options and sold US$299k worth of stock Oct 05
Akero Therapeutics announces closing of upsized public offering Sep 19 Shareholder Returns AKRO US Biotechs US Market 7D 106.6% 0.6% -0.5% 1Y 159.9% -3.8% 24.3%
See full shareholder returns
Return vs Market: AKRO exceeded the US Market which returned 24.3% over the past year.
Price Volatility Is AKRO's price volatile compared to industry and market? AKRO volatility AKRO Average Weekly Movement 29.3% Biotechs Industry Average Movement 11.4% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.3%
Stable Share Price: AKRO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AKRO's weekly volatility has increased from 16% to 29% over the past year.
About the Company Founded Employees CEO Website 2017 60 Andrew Cheng akerotx.com
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.
Show more Akero Therapeutics, Inc. Fundamentals Summary How do Akero Therapeutics's earnings and revenue compare to its market cap? AKRO fundamental statistics Market cap US$3.86b Earnings (TTM ) -US$237.22m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AKRO income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$237.22m Earnings -US$237.22m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/31 23:24 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Akero Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Zemansky BofA Global Research Alexandria Hammond BofA Global Research Edward Nash Canaccord Genuity
Show 13 more analysts 
